Freestone Capital Holdings’s AbbVie ABBV Stock Holding History

Freestone Capital Holdings’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-400	Closed	-$91.4K	–	573
2025 Q4	$91.4K	Buy	+400	New	+$91.1K	﹤0.01%	536

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Freestone Capital Holdings's ABBV Position: Q2 2026 in Review

Freestone Capital Holdings reduced its AbbVie (ABBV) stake by 5.9% in Q2 2026, selling an estimated $889K and leaving 65,869 shares worth $16.6M. The position accounts for 0.43% of the portfolio, ranked #37.

Freestone Capital Holdings first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Freestone Capital Holdings held 65,869 shares of AbbVie worth $16.6M as of Q2 2026.
Freestone Capital Holdings sold 4,133 AbbVie shares in Q2 2026, an estimated $889K.
AbbVie made up 0.43% of Freestone Capital Holdings's portfolio in Q2 2026, its #37 holding.
Freestone Capital Holdings first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Freestone Capital Holdings's 13F filing for Q2 2026, filed 31 Jul 2026.